HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E

Vaccine. 2012 Jan 20;30(5):832-6. doi: 10.1016/j.vaccine.2011.11.002. Epub 2011 Nov 12.


Immune responses to vaccines may be influenced or associated with allelic variants of host genes such as those encoding human leucocyte antigens (HLA). We have molecularly determined the HLA class II DR and DQ gene, allele and haploype profiles in HIV-1 negative ethnic Thai recipients of an HIV-1 prime boost vaccine regimen, designed to induce neutralizing antibody (NAb) responses to HIV-1 CRF01_AE. Non-response to vaccine associated with DRB1*11 (3/32 responders vs. 7/13 non-responders, p(c)=0.027) and DRB1*16:02 (0/32 responders vs. 4/13 non-responders, p(c)=0.078) alleles. Furthermore, vaccine recipients with HLA-DQ heterodimers encoded by DQA1*05:01 and DQB1*03:01 alleles, were much less likely to produce NAb (p=0.009). These data suggest that the lack of response to a vaccine designed to induce clade-specific NAb to HIV-1 is associated with the presence of certain HLA class II alleles and heterodimers in some Southeast Asians.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / immunology*
  • Alleles
  • Antibodies, Neutralizing / blood*
  • Genotype
  • HIV Antibodies / blood*
  • Histocompatibility Antigens Class II / genetics*
  • Histocompatibility Antigens Class II / immunology*
  • Human Experimentation
  • Humans
  • Thailand


  • AIDS Vaccines
  • Antibodies, Neutralizing
  • HIV Antibodies
  • Histocompatibility Antigens Class II